Clinical trials: Cancer Vaccine
Mucosal Melanoma, Recurrent Melanoma
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT01961115
- Testing
- Epacadostat, MELITAC 12.1 Peptide Vaccine
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.
- Trial name
- NCT02018458
- Testing
- LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Human Papilloma Virus, Warts
Intralesional HPV Vaccine for Condylomata
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
- Conditions
- Human Papilloma Virus, Warts, Warts, Genital, Condyloma
- Trial name
- NCT05087849
- Testing
- nonavalent human papillomavirus vaccine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Cognitive Side Effects of Cancer Therapy, Depression
Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
This randomized clinical trial uses an inactive typhoid vaccine to briefly stimulate an immune response in patients with stage I-IIIA breast cancer who received primary cancer treatment and studies whether patients' fitness…
- Conditions
- Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- IMPACT (NCT02415387)
- Testing
- typhoid vaccine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent)…
- Trial name
- NCT00450814
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Melanoma
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
This was a Phase 2, open-label study of the NY-ESO-1 ISCOMATRIX® (ISCOM) vaccine administered as an intramuscular injection given every 4 weeks to subjects with measurable advanced malignant melanoma.
- Trial name
- NCT00518206
- Testing
- NY-ESO-1 ISCOMATRIX® vaccine, Cyclophosphamide
- Where
- 2 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Ludwig Institute for Cancer Research
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV…
- Trial name
- NCT00937950
- Testing
- Gynaecological follow-up
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 2,022 people
- Sponsor
- GlaxoSmithKline
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
This extension study is conducted to assess the efficacy of the GSK 580299 vaccine against cervical intraepithelial neoplasia (CIN) lesions, cervical cancer and cytological abnormalities associated with human papillomavirus…
- Trial name
- NCT00929526
- Testing
- Liquid-based cytology (LBC) sampling, Blood sampling
- Where
- 13 sites in Japan
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC…
- Trial name
- ATALANTE-1 (NCT02654587)
- Testing
- OSE2101, Docetaxel, Pemetrexed
- Where
- 78 sites in United States, Czechia and 8 more
- Volunteers
- 219 people
- Sponsor
- OSE Immunotherapeutics
Diffuse Intrinsic Pontine Glioma, Glioma
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC). This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the Histone…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT02960230
- Testing
- K27M peptide, Nivolumab
- Where
- 15 sites in United States, Switzerland
- Volunteers
- 50 people
- Sponsor
- Sabine Mueller, MD, PhD
Cancer
Booster Dose Trial
The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S.
- Trial name
- NCT05016622
- Testing
- BNT162b2 vaccine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Montefiore Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04060277
- Testing
- Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer
- Trial name
- NCT03199872
- Testing
- RV001V
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- RhoVac APS
Human, Papillomavirus Infections
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
This study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).
- Trial name
- NCT00092547
- Testing
- V501
- Volunteers
- 1,781 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
- Trial name
- NCT03568058
- Testing
- Personalized Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Aaron Miller